← Back to Clinical Trials
Recruiting NCT05932745

NCT05932745 Effects of Novel E-cigarette Constituents on Adults TCORS 3.0

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05932745
Status Recruiting
Phase
Sponsor Yale University
Condition Nicotine Use Disorder
Study Type INTERVENTIONAL
Enrollment 66 participants
Start Date 2025-06-20
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
E-liquid coolant (No WS-3) for non-menthol (1)E-liquid coolant (No WS-3) for low (0.1%) menthol (1)E-liquid coolant (No WS-3) for high (2.0%) menthol (1)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 66 participants in total. It began in 2025-06-20 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.

Eligibility Criteria

Inclusion Criteria: * 18 years or older * Able to read and write * Some current e-cigarette use * Urine cotinine ≥200ng/ml * Willing to abstain from tobacco/nicotine use 2 hours prior to sessions Exclusion Criteria: * Current use of non-prescription substances besides nicotine, marijuana, alcohol * Any significant current medical or psychiatric condition * Known hypersensitivity to propylene glycol * Pregnant or lactating females * Uncontrolled asthma * Nut/e-liquid flavorant allergy * Current marijuana (tetrahydrocannabinol) vaping + E-cigarette or vaping use Associated Lung Injury (EVALI) symptoms * Dislike of menthol flavor

Contact & Investigator

Central Contact

Danielle Davis, PhD

✉ danielle.davis@yale.edu

📞 203-974-7607

Principal Investigator

Suchitra Krishnan-Sarin, PhD

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT05932745 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Nicotine Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05932745 currently recruiting?

Yes, NCT05932745 is actively recruiting participants. Contact the research team at danielle.davis@yale.edu for enrollment information.

Where is the NCT05932745 trial being conducted?

This trial is being conducted at New Haven, United States.

Who is sponsoring the NCT05932745 clinical trial?

NCT05932745 is sponsored by Yale University. The principal investigator is Suchitra Krishnan-Sarin, PhD at Yale University. The trial plans to enroll 66 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology